Company Registration No. 32266355
Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., that as of June 16, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments increased to 5.58% of the share capital and voting rights in the Company, and as of June 17, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments has been reduced to less than 5% of the shares and voting rights in the Company.
For additional information, please contact
Anders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO).